Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-PEDS1 pediatric lasmiditan trial for acute migraine
NL-OMON54273Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Pain freedom at 2 hours after dosing for lasmiditan high dose versus placebo. Started Jun 2020; status: recruiting.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON54273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54273.